amorchem header logo close button Menu
arrow leftBack to portfolio


This program centers on the optimization of small molecule hits initially discovered, and then validated, as part of a three-year program funded by GlaxoSmithKline and led at McGill’s Cystic Fibrosis Translational Research Centre directed by Drs. John Hanrahan and David Thomas, who are also the founders of Traffick Pharmaceuticals. These hits were selected based on their capacity to correct CFTR mistrafficking (“correctors”) or their ability to modulate CFTR function (“potentiators”) and ultimately optimized through a collaboration with NuChem Therapeutics. This program was sold to Vertex Pharmaceuticals.